Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

Giorgia Timon, Delia Ciardo, Alessia Bazani, Maria Garioni, Davide Maestri, Daniela De Lorenzo, Floriana Pansini, Raffaella Cambria, Elena Rondi, Federica Cattani, Giulia Marvaso, Dario Zerini, Barbara Vischioni, Mario Ciocca, Stefania Russo, Silvia Molinelli, Federica Golino, Valerio Scroffi, Damaris P. Rojas, Cristiana FodorGiuseppe Petralia, Luigi Santoro, Ottavio De Cobelli, Roberto Orecchia, Barbara A. Jereczek-Fossa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options. Methods: The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome). Results: The study is ongoing, and we expect to complete recruitment by the end of 2016. Conclusions: Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective. Trial registration: ClinicalTrials.gov identifier: NCT01913717.

Original languageEnglish
Pages (from-to)536-540
Number of pages5
JournalTumori
Volume102
Issue number5
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Prostatic Neoplasms
Radiotherapy
Therapeutics
Quality of Life
Magnetic Resonance Imaging
Radiation
Technology
Incidence
Clinical Studies

Keywords

  • Biomarkers
  • Dominant intraprostatic lesion (DIL)
  • High-precision radiotherapy
  • Hypofractionated radiotherapy
  • Magnetic resonance imaging (MRI)
  • Prostate cancer

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. / Timon, Giorgia; Ciardo, Delia; Bazani, Alessia; Garioni, Maria; Maestri, Davide; De Lorenzo, Daniela; Pansini, Floriana; Cambria, Raffaella; Rondi, Elena; Cattani, Federica; Marvaso, Giulia; Zerini, Dario; Vischioni, Barbara; Ciocca, Mario; Russo, Stefania; Molinelli, Silvia; Golino, Federica; Scroffi, Valerio; Rojas, Damaris P.; Fodor, Cristiana; Petralia, Giuseppe; Santoro, Luigi; De Cobelli, Ottavio; Orecchia, Roberto; Jereczek-Fossa, Barbara A.

In: Tumori, Vol. 102, No. 5, 01.09.2016, p. 536-540.

Research output: Contribution to journalArticle

Timon, Giorgia ; Ciardo, Delia ; Bazani, Alessia ; Garioni, Maria ; Maestri, Davide ; De Lorenzo, Daniela ; Pansini, Floriana ; Cambria, Raffaella ; Rondi, Elena ; Cattani, Federica ; Marvaso, Giulia ; Zerini, Dario ; Vischioni, Barbara ; Ciocca, Mario ; Russo, Stefania ; Molinelli, Silvia ; Golino, Federica ; Scroffi, Valerio ; Rojas, Damaris P. ; Fodor, Cristiana ; Petralia, Giuseppe ; Santoro, Luigi ; De Cobelli, Ottavio ; Orecchia, Roberto ; Jereczek-Fossa, Barbara A. / Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. In: Tumori. 2016 ; Vol. 102, No. 5. pp. 536-540.
@article{a88f10f5e36d434ab91db3a6602f68ed,
title = "Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion",
abstract = "Introduction: Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options. Methods: The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome). Results: The study is ongoing, and we expect to complete recruitment by the end of 2016. Conclusions: Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective. Trial registration: ClinicalTrials.gov identifier: NCT01913717.",
keywords = "Biomarkers, Dominant intraprostatic lesion (DIL), High-precision radiotherapy, Hypofractionated radiotherapy, Magnetic resonance imaging (MRI), Prostate cancer",
author = "Giorgia Timon and Delia Ciardo and Alessia Bazani and Maria Garioni and Davide Maestri and {De Lorenzo}, Daniela and Floriana Pansini and Raffaella Cambria and Elena Rondi and Federica Cattani and Giulia Marvaso and Dario Zerini and Barbara Vischioni and Mario Ciocca and Stefania Russo and Silvia Molinelli and Federica Golino and Valerio Scroffi and Rojas, {Damaris P.} and Cristiana Fodor and Giuseppe Petralia and Luigi Santoro and {De Cobelli}, Ottavio and Roberto Orecchia and Jereczek-Fossa, {Barbara A.}",
year = "2016",
month = "9",
day = "1",
doi = "10.5301/tj.5000547",
language = "English",
volume = "102",
pages = "536--540",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion

AU - Timon, Giorgia

AU - Ciardo, Delia

AU - Bazani, Alessia

AU - Garioni, Maria

AU - Maestri, Davide

AU - De Lorenzo, Daniela

AU - Pansini, Floriana

AU - Cambria, Raffaella

AU - Rondi, Elena

AU - Cattani, Federica

AU - Marvaso, Giulia

AU - Zerini, Dario

AU - Vischioni, Barbara

AU - Ciocca, Mario

AU - Russo, Stefania

AU - Molinelli, Silvia

AU - Golino, Federica

AU - Scroffi, Valerio

AU - Rojas, Damaris P.

AU - Fodor, Cristiana

AU - Petralia, Giuseppe

AU - Santoro, Luigi

AU - De Cobelli, Ottavio

AU - Orecchia, Roberto

AU - Jereczek-Fossa, Barbara A.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Introduction: Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options. Methods: The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome). Results: The study is ongoing, and we expect to complete recruitment by the end of 2016. Conclusions: Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective. Trial registration: ClinicalTrials.gov identifier: NCT01913717.

AB - Introduction: Of the different treatments for early prostate cancer, hypofractionated external-beam radiotherapy is one of the most interesting and studied options. Methods: The main objective of this phase II clinical study is to evaluate the feasibility, in terms of the incidence of acute side effects, of a new ultra-hypofractionated scheme for low- or intermediate-risk prostate cancer patients treated with the latest imaging and radiotherapy technology, allowing dose escalation to the dominant intraprostatic lesion identified by multiparametric magnetic resonance imaging. Secondary endpoints of the study are the evaluation of the long-term tolerability of the treatment in terms of late side effects, quality of life, and efficacy (oncological outcome). Results: The study is ongoing, and we expect to complete recruitment by the end of 2016. Conclusions: Like in previous studies, we expect ultra-hypofractionated radiation treatment for prostate cancer to be well tolerated and effective. Trial registration: ClinicalTrials.gov identifier: NCT01913717.

KW - Biomarkers

KW - Dominant intraprostatic lesion (DIL)

KW - High-precision radiotherapy

KW - Hypofractionated radiotherapy

KW - Magnetic resonance imaging (MRI)

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84995644744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995644744&partnerID=8YFLogxK

U2 - 10.5301/tj.5000547

DO - 10.5301/tj.5000547

M3 - Article

AN - SCOPUS:84995644744

VL - 102

SP - 536

EP - 540

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -